

## **EXTRAORDINARY INFORMATION**

### **On the Resolution of the CEO regarding the invalidation of shares and issuance of new shares**

Egis Pharmaceuticals PLC (Egis) hereby discloses the attached Resolution of the CEO declaring invalid as of December 11, 2013 all those Egis shares whose transfer by the shareholders to the securities account of Arts et Techniques du Progrès (Servier) has not been made during the period announced pursuant to the Section 76/D of the Act no. CXX. of 2001 on the Capital Markets ("CMA") and expired on November 29, 2013.

In accordance with the Resolution, the invalid shares will be deleted and new shares will be issued instead for the benefit of Arts et Techniques du Progrès.

Egis has requested the Central Clearing House and Depository (Budapest) Ltd. to contribute in the process of partial deletion of the invalidated shares and in the issuance of the new shares in the same number and with the same rights. The date of invalidation, deletion and issuance will be December 11, 2013.

Based on the above, Arts et Techniques du Progrès (Servier) will become the owner of all Egis shares.

Budapest, December 2, 2013

Egis Pharmaceuticals PLC

WS1701.165455.1

Egis Pharmaceuticals PLC  
H-1106 Budapest, Keresztúri út 30-38.  
Postal address: H-1475 Budapest 10 P.O. Box 100  
Phone: +36-1-803-5555, Fax: +36-1-803-5529  
Metropolitan Court of Budapest: 01-10-041762

## Resolution

### On the invalidation of shares, issuance of new shares

Egis Pharmaceuticals Public Limited Company (H-1106 Budapest, Keresztúri út 30-38, registration number: 01-10-041762, the "Issuer" or "Egis") resolves that pursuant to its statutory obligation set out in Section 76/D (5) of the Act no. CXX. of 2001 on the Capital Markets (the "CMA"), 60,932 pieces of shares, issued by Egis as part of the series of dematerialized ordinary registered shares (ISIN: HU0000053947), representing equal voting rights, **shall be invalid as of December 11, 2013**, and **new shares** (in the same number and with equal voting rights) **shall be issued instead**, which new shares will be made available to the offeror Arts et Techniques du Progrès (Address: 25 rue Eugène Vignat, 45000 Orléans, France, the "Offeror") which exercised its Call Option Right pursuant to Subsections 76/D (1) and (2) of the CMA. Based on the above, custodians (investment service providers) of the shareholders holding the invalidated shares are obliged to transfer such invalidated shares on December 11, 2013 not later than until 14:00 pm to the securities account of the Issuer No. 0560/000000. The Issuer shall transfer the countervalue of HUF 28,000 for each invalidated share to the respective custodians' accounts of all concerned shareholders. Egis shall contact with each concerned custodian on or after December 11, 2013 in relation to the payment of the countervalue.

#### Reasoning:

The Offeror has made a voluntary public purchase offer for all shares of Egis, thereafter pursuant to Subsections 76/D (1) and (2) of the CMA, and in accordance with the declaration disclosed on the websites [www.bet.hu](http://www.bet.hu), [www.egis.hu](http://www.egis.hu) and [www.kozzetetelek.hu](http://www.kozzetetelek.hu) on November 14, 2013, exercised its Call Option Right in respect of all shares not acquired during the voluntary public purchase offer. The Offeror in its declaration regarding the Call Option Right notified the shareholders regarding their obligation to transfer their Egis shares until November 29, 2013 at the latest to the specified securities account of the Offeror. Until the expiry of the above deadline altogether 60,932, ie sixty thousand-ninehundredthirtytwo pieces of ordinary shares have not been transferred to the Offeror's account. In respect of these shares the Issuer shall act in accordance with the foregoing pursuant to the statutory authorization and obligations provided by the Subsection 76/D (5) of the CMA.

Budapest, December 2, 2013

Dr Hodász István Balázs  
Chief Executive Officer  
Egis Pharmaceuticals PLC